Advances in eicosanoid research, novel therapeutic implications

Biochemical and Biophysical Research Communications

Volumn 396, Issue 1, 2010, Pages 135-139

  Haeggström, Jesper Z ^a   Rinaldo Matthis, Agnes ^a   Wheelock, Craig E ^a   Wetterholm, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Asthma; Atherosclerosis; Drug design; Eicosanoids; Inflammation; Leukotriene

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; G PROTEIN COUPLED RECEPTOR; ICOSANOID; LATANOPROST; LEUKOTRIENE; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPID; LIPOXIN; MISOPROSTOL; MONTELUKAST; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; THOMBYL; THROMBOXANE; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; COLON CANCER; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG DESIGN; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GLAUCOMA; HUMAN; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; THROMBOSIS;

ARACHIDONATE 5-LIPOXYGENASE; BIOMEDICAL RESEARCH; CARRIER PROTEINS; CYCLOOXYGENASE INHIBITORS; CYTOSOL; DRUG DESIGN; EICOSANOIC ACIDS; GROUP IV PHOSPHOLIPASES A2; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MEMBRANE PROTEINS; RECEPTORS, LEUKOTRIENE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952308123     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.03.140     Document Type: Article

References (48)

1. 2 structure/function, mechanism, and signaling. J. Lipid Res. 50 Suppl. (2009) S237-242
2. 2 in allergic response and parturition. Nature 390 (1997) 618-622
3. 2 reveals a novel topology and catalytic mechanism. Cell 97 (1999) 349-360
4. 2. J. Cell Biol. 145 (1999) 1219-1232
5. 2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J. Neuroimmunol. 204 (2008) 29-37
6. Smith W.L., Dewitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
7. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352 (2005) 1092-1102
8. Fries S., Grosser T., Price T.S., et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130 (2006) 55-64
9. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
10. Wallace P., and Del Soldato J.L. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. 17 (2003) 11-20
11. Samuelsson B., Morgenstern R., and Jakobsson P.J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 59 (2007) 207-224
12. Radmark O., Werz O., Steinhilber D., et al. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 32 (2007) 332-341
13. Gillmor S.A., Villasenor A., Fletterick R., et al. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat. Struct. Biol. 4 (1997) 1003-1009
14. Neau D.B., Gilbert N.C., Bartlett S.G., et al. The 1.85 A structure of an 8R-lipoxygenase suggests a general model for lipoxygenase product specificity. Biochemistry 48 (2009) 7906-7915
15. Berger W., De Chandt M.T.M., and Cairns C.B. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract. 61 (2007) 663-676
16. Peters-Golden M., and Brock T.G. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. 487 (2001) 323-326
17. Bain G., King C.D., Rewolinski M., et al. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP). Clin. Pharmacol. Ther. 87 (2010) 437-444
18. Stock N., Baccei C., Bain G., et al. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679) - a potent FLAP inhibitor. Bioorg. Med. Chem. Lett. 20 (2010) 213-217
19. Claria J., and Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 92 (1995) 9475-9479
20. Serhan C.N., Chiang N., and Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8 (2008) 349-361
21. 4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J. Pharmacol. Exp. Ther. 321 (2007) 1154-1160
22. 4 hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness, Am. J. Respir. Crit. Care Med., in press. Epub ahead of print.
23. Drazen J.M., Israel E., and O'byrne P. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 340 (1999) 197-206
24. Funk C.D. Lipoxygenase pathways as mediators of early inflammatory events in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1204-1206
25. Qiu H., Gabrielsen A., Agardh H.E., et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. USA 103 (2006) 8161-8166
26. 4 hydrolase, a bifunctional enzyme in inflammation. Nat. Str. Biol. 8 (2001) 131-135
27. 4 biosynthesis. J. Biol. Chem. 279 (2004) 50639-50642
28. 4 hydrolase: implications for M1 aminopeptidases and inhibitor design. Chem. Biol. 15 (2008) 920-929
29. 4 hydrolase. Bioorg. Med. Chem. 16 (2008) 4963-4983
30. 4 hydrolase inhibitors using metabolomics biased fragment crystallography. J. Med. Chem. 52 (2009) 4694-4715
31. Ago H., Kanaoka Y., Irikura D., et al. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 448 (2007) 609-612
32. 4 synthase. Nature 448 (2007) 613-616
33. Ferguson A.D., Mckeever B.M., Xu S., et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317 (2007) 510-512
34. 2. Proc. Natl. Acad. Sci. USA 105 (2008) 11110-11115
35. 2α. J. Biol. Chem. 284 (2009) 301-305
36. 4 that mediates chemotaxis. Nature 387 (1997) 620-624
37. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 49 (2009) 123-150
38. 4 receptor type 1 that is specifically involved in Gi activation. J. Biol. Chem. 282 (2007) 3998-4006
39. 4 binding to BLT1. Biochemistry 45 (2006) 5733-5744
40. Lynch K.R., O'neill G.P., Liu Q., et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399 (1999) 789-793
41. Heise C.E., O'dowd B.F., Figueroa D.J., et al. Characterization of the human cysteinyl leukotriene 2 (CysLT2) receptor. J. Biol. Chem. 275 (2000) 30531-30536
42. Sjostrom M., Johansson A.S., Schroder O., et al. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23 (2003) e37-41
43. Hui Y., Cheng Y., Smalera I., et al. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 110 (2004) 3360-3366
44. Jiang W., Hall S.R., Moos M.P., et al. Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. Am. J. Pathol. 172 (2008) 592-602
45. Ciana P., Fumagalli M., Trincavelli M.L., et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 25 (2006) 4615-4627
46. 4. Proc. Natl. Acad. Sci. USA 106 (2009) 11685-11690
47. 4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc. Natl. Acad. Sci. USA 105 (2008) 16695-16700
48. 4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J. Exp. Med. 206 (2009) 2543-2555